However, we estimated that there were approximately 3 times as many people who died from NSCLC with PD-L1 between 0% and 50% than NSCLC with PD-L1 greater than 50% during 2018, and the absolute numbers of individuals who develop and die from NSCLC with PD-L1 between 0% and 50% is what is driving the benefit. This evidence concerns the gene CD274 and non-small cell lung carcinoma.